Merck KGaA bolstered by Erbitux and Rebif in Q1
This article was originally published in Scrip
Executive Summary
Merck KGaA's first-quarter sales rose by 13% to €2.1 billion, in large part due to strongly rebounding growth in its liquid crystals business – which had been hit hard by the global financial crisis last year – but also helped by sales of its key biological products Erbitux (cetuximab) and Rebif (interferon beta-1a).